AU2019331913A1 - Taurolidine treatment for myc-expressing tumors in mammalian bodies - Google Patents

Taurolidine treatment for myc-expressing tumors in mammalian bodies Download PDF

Info

Publication number
AU2019331913A1
AU2019331913A1 AU2019331913A AU2019331913A AU2019331913A1 AU 2019331913 A1 AU2019331913 A1 AU 2019331913A1 AU 2019331913 A AU2019331913 A AU 2019331913A AU 2019331913 A AU2019331913 A AU 2019331913A AU 2019331913 A1 AU2019331913 A1 AU 2019331913A1
Authority
AU
Australia
Prior art keywords
composition
taurinamide
taurultam
dosage range
taurolidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2019331913A
Other languages
English (en)
Inventor
Robert Diluccio
Bruce Reidenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cormedix Inc
Original Assignee
Cormedix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cormedix Inc filed Critical Cormedix Inc
Publication of AU2019331913A1 publication Critical patent/AU2019331913A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2019331913A 2018-08-31 2019-09-03 Taurolidine treatment for myc-expressing tumors in mammalian bodies Pending AU2019331913A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862725650P 2018-08-31 2018-08-31
US62/725,650 2018-08-31
PCT/US2019/049266 WO2020047530A1 (en) 2018-08-31 2019-09-03 Taurolidine treatment for myc-expressing tumors in mammalian bodies

Publications (1)

Publication Number Publication Date
AU2019331913A1 true AU2019331913A1 (en) 2021-04-29

Family

ID=69643283

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019331913A Pending AU2019331913A1 (en) 2018-08-31 2019-09-03 Taurolidine treatment for myc-expressing tumors in mammalian bodies

Country Status (7)

Country Link
EP (1) EP3843747A4 (zh)
JP (1) JP2021535167A (zh)
KR (1) KR20210054544A (zh)
CN (1) CN113226325A (zh)
AU (1) AU2019331913A1 (zh)
CA (1) CA3111100A1 (zh)
WO (1) WO2020047530A1 (zh)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9005856D0 (en) * 1990-03-15 1990-05-09 Geistlich Soehne Ag Compositions
US7151099B2 (en) * 1998-07-31 2006-12-19 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Use of taurolidine and/or taurultam for treatment of abdominal cancer and/or for the prevention of metastases
DE60030770T2 (de) * 1999-12-06 2007-09-06 Rhode Island Hospital Verwendung von taurolidin oder taurultam zur herstellung eines medikaments zur behandlung von ovarialkarzinomen
CN100519525C (zh) * 1999-12-06 2009-07-29 葛兰素集团有限公司 芳香砜类及其医疗用途
US20080171738A1 (en) * 2001-04-03 2008-07-17 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of Breast Cancer
CA2482687C (en) * 2003-09-29 2012-11-20 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of mesothelioma
WO2007020509A1 (en) * 2005-08-15 2007-02-22 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Combination of methylol transfer agents with tumour-inhibiting proteins or peptides and the use thereof for the treatment of cancer or tumor growth
US7928102B2 (en) * 2006-01-06 2011-04-19 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Irradiated compositions and treatment of cancers with radiation in combination with taurolidine and/or taurultam
ES2614878T3 (es) * 2010-06-01 2017-06-02 Geistlich Pharma Ag Métodos y composiciones para terapia farmacéutica oral
EP3402527B1 (en) * 2016-01-11 2022-09-28 CorMedix Inc. Therapeutic nanoparticles for the treatment of neuroblastoma and other cancers
ES2945712T3 (es) * 2016-03-18 2023-07-06 Geistlich Pharma Ag Método de tratamiento de cáncer de mama triple negativo

Also Published As

Publication number Publication date
CA3111100A1 (en) 2020-03-05
CN113226325A (zh) 2021-08-06
EP3843747A4 (en) 2022-12-28
EP3843747A1 (en) 2021-07-07
WO2020047530A1 (en) 2020-03-05
JP2021535167A (ja) 2021-12-16
KR20210054544A (ko) 2021-05-13

Similar Documents

Publication Publication Date Title
US20170266293A1 (en) Methods of treating cancers with therapeutic nanoparticles
CZ290120B6 (cs) Sdruľená kompozice paclitaxelu, docetaxelu nebo jejich analogu
JP6076317B2 (ja) 対象において持続的治療薬濃度を実現するための組成物及び方法
Naraharisetti et al. In vivo performance of implantable biodegradable preparations delivering Paclitaxel and Etanidazole for the treatment of glioma
AU2008260203B2 (en) Metal complexes incorporated within biodegradable nanoparticles and their use
US20230390300A1 (en) Neuroblastoma treatment with taurolidine hydrolysis products
JP2009292837A (ja) より効能が大きく副作用の少ない癌治療方法
US20220323451A1 (en) Taurolidine treatment for myc-expressing tumors in mammalian bodies
AU2019331913A1 (en) Taurolidine treatment for myc-expressing tumors in mammalian bodies
KR20210050544A (ko) 타우로리딘 가수분해 생성물을 이용한 신경모세포종 치료
US20220323450A1 (en) Methods and compositions for treating neuroblastoma in a juvenile mammalian body
WO2023196545A1 (en) Cancer treatments using mta-cooperative prmt5 inhibitors
Zhang et al. Co-delivery of sorafenib and metformin from amphiphilic polypeptide-based micelles for colon cancer treatment
CN113164491A (zh) 用于治疗幼年哺乳动物体内神经母细胞瘤的方法和组合物
Karmali et al. Combinatorial treatment with carboxyamidotriazole-orotate and temozolomide in sc-implanted human LOX IMVI melanoma xenografts
WO2008135792A1 (en) Pm00104 compound for use in cancer therapy
Akotiah et al. Drug Targeting and Therapeutic Management of Chronic Myeloid Leukemia: Conventional and Nanotherapeutic Drug Options
AU2016253153A1 (en) Compositions for the treatment of cancer
Cui et al. Modest anti-cancer activity of a bile acid acylated heparin derivative in a PC14PE6 induced orthotopic lung cancer model
JP2023108999A (ja) 抗がん剤含有シート
CN117083086A (zh) 腺苷二磷酸核糖在放射和／或抗癌治疗辅助疗法中的应用
CN112618479A (zh) 多西紫杉醇/聚乳酸抗肿瘤植入支架的制备方法
WO2008033039A1 (en) Cancer treatment
WO2010109450A1 (en) Rhodamine 6g for use in treating cancerous cells